updraftplus domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/aonyeani76/cryptocurrencypanther/wp-includes/functions.php on line 6131hustle domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/aonyeani76/cryptocurrencypanther/wp-includes/functions.php on line 6131wpforms-lite domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/aonyeani76/cryptocurrencypanther/wp-includes/functions.php on line 6131With the second phase concluded, the Phase 3 melanoma trial will begin soon.
Biotechnology company Moderna Inc (NASDAQ: MRNA) experienced shares decline on Monday as an update on its cancer vaccine hit Wall Street. Moderna lost more than 8% after it released new trial results on the personalized cancer vaccine, which it is developing with another pharmaceutical company Merck & Co Inc (NYSE: MRK). While MRNA closed down, Merck also shed 0.26% to close at $115.01.
How come Moderna shares plunged despite the company announcing promising data from its cancer vaccine trial? Both companies announced the first presentation of details results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), in combination with Merck’s anti-PD-1 therapy in patients suffering from stage III/1V skin cancer melanoma. According to the findings, combining the Moderna cancer vaccine with Merck’s blockbuster drug Keytruda reduces the risk of melanoma recurrence by 44% compared with administering Keytruda alone. Additionally, almost 80% of participants who received the Moderna vaccine and Keytruda were cancer-free for 18 months. This is compared with 62% of the participants who only got Keytruda.
M.D. Moderna’s Senior Vice President and Head of Development, Therapeutics and Oncology, Dr. Kyle Holen, commented on the motivating results. He said the results encourage the mRNA’s potential “as an individualized neoantigen therapy” to positively impact patients with high-risk resected melanoma. The Dr. explained that the Moderna vaccine combined with Keytruda could be the solution to extending patients’ lives. With the second phase concluded, the Phase 3 melanoma trial will begin soon. Holen also mentioned testing expansion into lung cancer and beyond.
Also, the senior president, head of global clinical development, and chief medical officer at Merck Research Laboratories Dr. Eliav Barr, talked about the results of the latest trial.
“Data from KEYNOTE-942 provide evidence for the potential of mRNA-4147 (V940) in combination with KEYTRUDA to improve recurrence-free survival when given to patients with resected high-risk melanoma. These data support the potential of mRNA-4157 (V940) in combination with KEYTRUDA to help fight melanoma earlier and warrant investigation of the combination in a larger Phase 3 trial. We look forward to studying mRNA-4157 (V940) and KEYTRUDA in a variety of other early-stage cancers.”
Following the trial results, the US Food and Drug Administration and European Medicines Agency granted Breakthrough Therapy Designation and the PRIME scheme, respectively, for mRNA-4157 (V940) in combination with KEYTRUDA for the adjuvant treatment of patients with high-risk melanoma after complete resection.
While a part of Wall Street becomes optimistic about the Moderna cancer vaccine in combination with Keytruda, some are skeptical. Although analysts from SVB Securities agree that the results show that the vaccine has potential, they had some reservations. The analysts added that the treatment method is new and untested. Hence, they noted that the firm does not believe accelerated approval is an option. On the other hand, Tim Anderson of Wolfe Research wrote that Moderna and Merck’s stakeholders are “cautiously optimistic at best.”
Ibukun is a crypto/finance writer interested in passing relevant information, using non-complex words to reach all kinds of audience.
Apart from writing, she likes to see movies, cook, and explore restaurants in the city of Lagos, where she resides.
Alpha Metallurgical Resources Inc (NYSE:AMR) is known as a leading American coal supplier, and over the past year, delivered shocking returns for bullish traders and investors.
Since March 2021, Alpha Metallurgical stock’s 1-year return has outperformed several of the world’s most popular pharmaceutical, telecommunications stocks and cryptocurrencies: Moderna Inc (NASDAQ:MRNA), Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), Globalstar, Inc. (NASDAQ:GSAT) and Dogecoin (CRYPTO: DOGE).
Alpha Metallurgical is a Tennessee-based coal mining company with operations across Virginia and West Virginia. The company’s portfolio of mining operations consists of underground mines, surface mines and coal preparation plants.
Alpha Metallurgical extracts, processes and markets met and thermal coal from deep and surface mines for sale to steel and coke producers, industrial customers and electric utilities. Alpha Metallurgical was incorporated in 2016 and is headquartered in Bristol, Tennessee.
Here’s how the returns break down from March 2021 to present:
And finally, Alpha Metallurgical is up from $13.13 to $132.06 for a return of 905.79%
Also Read: This Emissions Cleanup Company Wants To Make Solving The Coal Ash Crisis Profitable
There has been no dearth of interesting news from the technology, cryptocurrency and corporate sectors despite the long Labor Day weekend. Here is a quick roundup of the top five stories that investors may have missed.
1. El Salvador Buys Bitcoin Ahead Of Making It Legal Lender: Bitcoin (CRYPTO: BTC) is officially a legal tender in El Salvador beginning Tuesday and ahead of that, late Monday, the country’s President Nayib Bukele announced that the country has purchased nearly $21 million worth of the apex cryptocurrency, in first such move anywhere in the world.
See Also: How To Buy Bitcoin (BTC)
2. Elon Musk “Likes” Dogecoin’s Wife: Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk apparently ‘likes’ meme cryptocurrency Dogecoin’s (CRYPTO: DOGE) ‘wife,’ Wifedoge (CRYPTO: WIFEDOGE), which jumped over 3,000% in a single day to exceed a market capitalization of $2.32 million last week. However, the altcoin failed to stay the course and its capitalization plunged to $301,406 within two days.
3. Moderna Boosters Could Face Delay: Moderna Inc.’s (NASDAQ: MRNA) COVID-19 booster shot may not be rolled out in the week of Sept. 20 as the company is yet to submit the required data to the U.S. Food and Drug Administration, according to U.S. President Joe Biden’s Chief Medical Adviser Anthony Fauci. However, the Pfizer Inc. (NYSE: PFE)-BioNTech SE (NASDAQ: BNTX) booster shot is on track as the companies have submitted the necessary data.
4. Musk Agrees With Cathie Wood’s $3,000 Tesla Price Target: Elon Musk said he agrees with Cathie Wood-led Ark Invest’s $3,000 price target for Tesla by 2025, provided the electric vehicle maker executes “really well.” Tesla currently trades at $733 per share.
5. Boeing Woes Continue: Boeing Co. (NYSE: BA) may not be able to deliver the 787 Dreamliner jets until at least late October as the U.S. Federal Aviation Administration (FAA) has rejected that the company’s recent proposal to inspect them.
Meanwhile, European budget airline Ryanair Holdings Plc (NASDAQ: RYAAY), one of Boeing’s biggest customers, said it has terminated talks with the aircraft manufacturer over the purchase of 737 Max 10 jets due to differences over pricing.
What Else: Among other stories from the weekend, investors would want to check out the Benzinga EV week in review, the week ahead in Biotech, why the National Football League (NFL) has banned teams from selling sponsorships to cryptocurrency trading firms or non fungilble tokens (NFTs), and Olympic gold medal-winning heavyweight wrestler Gable Stevenson reportedly joining World Wrestling Entertainment Inc. (NYSE: WWE).
In addition, Walt Disney Co.’s (NYSE: DIS) new Marvel Cinematic Universe release “Shang-Chi and the Legend of the Ten Rings” grossed $71.4 million during the Labor Day weekend, surpassing the Labor Day opening record of $30.6 million set by “Halloween” in 2007 and Wood’s firm Ark Invest has completely divested its stake in Alibaba Group Holding Ltd. (NYSE: BABA).
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
]]>